Company: MIRA
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001641172-25-010301
Chunk: 13

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-05-14
Form: 10-Q
Item: Item 8
Chunk 13
---
 Financial Condition and Results of Operations”
are forward-looking statements.

We
have based these forward-looking statements on our current expectations, assumptions, estimates and projections. While we believe these
expectations, assumptions, estimates, and projections are reasonable, such forward-looking statements are only predictions and involve
known and unknown risks and uncertainties, many of which are beyond our control. These and other important factors, including those discussed
in this Report under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations”
may cause our actual results, performance, or achievements to differ materially from any future results, performance or achievements
expressed or implied by these forward-looking statements, or could affect our share price. Important factors that could cause actual
results or events to differ materially from those expressed in forward-looking statements include, but are not limited to, the following:

    ●
    our
    reliance on related parties for potential funding and our license for Ketamir-2;

    ●
    our potential transaction with SKNY Pharmaceuticals, Inc.;

    ●
    our
    ability to obtain and maintain regulatory approval of our product candidates;

    ●
    our
    ability to successfully commercialize and market our product candidates, if approved;

    ●
    our
    ability to contract with third-party suppliers, manufacturers and other service providers and their ability to perform adequately;

    ●
    the
    potential market size, opportunity, and growth potential for our product candidates, if approved;

    ●
    our
    ability to obtain additional funding for our operations and development activities;

    ●
    the
    accuracy of our estimates regarding expenses, capital requirements and needs for additional financing;

    ●
    the
    initiation, timing, progress and results of our clinical studies and clinical trials, and our research and development programs;

    ●
    the
    timing of anticipated regulatory filings;

    ●
    the
    timing of availability of data from our clinical trials;

    ●
    our
    future expenses, capital requirements, need for additional financing, and the period over which we believe that our existing cash
    and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements;

    ●
    our
    ability to retain the continued service of our key professionals and to identify, hire and retain additional qualified professionals;

    ●
    our
    ability to advance product candidates into, and successfully complete, clinical trials;

    ●
    our
    ability to recruit and enroll suitable